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Recent studies have reported an imbalance between n6 and n3 fatty acids (AA and DHA) in subjects with CF. Alterations in fatty acid
amounts are present in CFTR-expressing tissues, plasma and in circulating blood cells. It has been reported that the correction of
polyunsaturated fatty acid deficiency reversed the organ pathologies observed in CF knockout mice.
We describe a CF child with an unusual clinical course presenting high molar percentage of DHA in plasma and red cells membrane
during supplementation with 5-methyltetrahydrofolate and vitamin B12.
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The presence of a fatty acid defect is well known in
subjects with cystic fibrosis (CF) mutations [1,2]. It has
been suggested that fatty acid abnormalities could play an
important role in the phenotypic expression of CF disease;
in particular, it seems that administration of high doses of
oral docosahexaenoic acid (DHA) in CF knockout mice may
reverse the pathological changes observed in cystic fibrosis
transmembrane conductance regulator (CFTR) regulated
tissues [3].
Alterations in phospholipid fatty acid amounts are
present in the plasma, red blood cells membrane and tissue
expressing CFTR from CF patients [4,5]. Lower levels of
linoleic acid and docosahexaenoic acid (DHA) have been
reported even in CF patients with pancreatic sufficiency and
adequate dietary intake [6]. Evidence for primary abnor-
malities in fatty acid metabolism in CF also includes the
essential fatty acid deficiency in cord-blood phospholipids
of CF newborns [7].1569-1993/$ - see front matter D 2006 European Cystic Fibrosis Society. Publish
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percentage of DHA in plasma and red cells membrane
during supplementation with 5-methyltetrahydrofolate (5-
MTHF).2. Case report
The child was born at term and appeared healthy but
the neonatal screening test was positive for CF (IRT was
143Ag/l), as also confirmed by the increased chloride level
at the sweat test (88mEq/kg). Genotype was investigated
and two mutations in the CFTR gene were identified
(deltaI507/4382delA). In the child’s first 4 months of life
the levels of chymotrypsin were low or borderline (3.35–
1.8–4.8–2.6 U/g stool), but pancreatic enzyme replace-
ment was not started because the child’s growth weight
was regular.
Supposing that changes in fatty acid composition could
be induced by phospholipid methylation related to folic acid
supplementation, as several studies suggest [8,9], we
decided to investigate the effect of treatment with 5-MTHF
on the phospholipid fatty acid pattern of plasma and red
blood cell membranes in the CF child and in her mother.5 (2006) 197 – 199ed by Elsevier B.V. All rights reserved.
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Fig. 1. Metabolic cycle of methionine.
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mother began a daily supplementation of 15mg of 5-MTHF
and the subsequent dosage of folic acid in her milk was of
51.4Ag/ml. The child suckled about 400 ml per day, and 6
months later, plasma and red blood cell folate levels were
respectively 92ng/ml and 306ng/ml for the mother and
51ng/ml and 403ng/ml for the child.
The plasma DHA level of the child increased during 5-
MTHF supplementation from 1.62% to 3.16% and, surpris-
ingly, it was higher than that observed in a healthy age-
matched control child (1.96%). A higher relative molar
percentage of DHA was also present in the erythrocyte
membrane lipids of the CF child compared to the control,
8.94% and 5.98%, respectively. High values of plasma and
erythrocyte DHA were reconfirmed later.
The mother’s plasma DHA level also significantly in-
creased during the 5-MTHF treatment from 1.75% to 2.62%
and, similarly, the value of DHA in red blood cells membrane
was higher than in a healthy control (6.16% vs. 5.3%).
Unfortunately, the storage of the red blood cells collected
before treatment was inadequate and, therefore, it was not
possible to carry out a comparison before and after
treatment.
It has been 6 years since the beginning of the folic acid
supplementation and 5-MTHF is presently given to the CF
child at the dose of 30 mg per week; vitamin B12 has been
added. During this period the child has been free from
clinical or radiological lung disease and her growth rate has
been normal without using pancreatic extract. Two months
after the beginning of the treatment with 5-MTHF, stool
chymotryptic activity appeared to be normal, increasing to
higher levels at the following checks.Methyltransferases
S-adenosyl-methionine
Phosphatidylcholine
Fig. 2. Membrane phospholipid methylation.3. Discussion
This case prompts us to speculate that changes in fatty
acid composition could be mediated by an increase ofmethionine bioavailability, which is 5-MTHF dependent.
Methionine is necessary to guarantee sufficient S-adenosyl-
methionine synthesis (Fig. 1). S-adenosylmethionine partic-
ipates in most cellular transmethylation reactions including
phosphatidylethanolamine (PE) methylation (Fig. 2). Phos-
phaditylcholine (PC) produced by this pathway is enriched
in polyunsaturated fatty acids [9]. Recently, it has been
demonstrated that the plasma PE/PC ratio is significantly
higher in CF children than in control children whereas
methionine is lower [10]. The disrupted methionine and
phospholipid metabolism could explain the reduced levels
of DHA in CF children, even if the reasons for this have still
to be clarified.
Another study suggests the importance of methylation in
CF patients, demonstrating that only methylated phospho-
lipids appear to have an improving effect on mutant CFTR
by increasing the expression of deltaF508 CFTR and
promoting the expression of higher molecular weight CFTR
forms [11]. Moreover, it has been proved that methylation in
the promoter of the epithelial amiloride-sensitive Na
C. Scambi et al. / Journal of Cystic Fibrosis 5 (2006) 197–199 199channel gene inhibits the hyperactivity of this channel in
human CF airway epithelia cells [12].
In conclusion, we suppose that changes in methylation
may have pathophysiological significance for the CF
clinical picture, as supported by the present case. We are
planning further investigations on the effects of 5-MTHF
supplementation to evaluate its possible clinical applications
in CF patients.References
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